Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $115.00 price objective on the biotechnology company’s stock.

Several other equities analysts have also recently commented on the company. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, B. Riley Financial lifted their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.07.

Arrowhead Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ:ARWR opened at $55.90 on Thursday. The firm has a fifty day moving average price of $75.53 and a two-hundred day moving average price of $75.86. The company has a market cap of $7.87 billion, a price-to-earnings ratio of -24.84 and a beta of 1.29. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a one year low of $36.57 and a one year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The firm had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same period in the previous year, the company posted ($1.26) EPS. The company’s revenue for the quarter was up 171.0% compared to the same quarter last year. Analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Adeoye Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Perry sold 11,600 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its holdings in shares of Arrowhead Pharmaceuticals by 243.8% in the second quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company’s stock worth $16,459,000 after purchasing an additional 143,192 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth $20,859,000. Siren L.L.C. increased its stake in shares of Arrowhead Pharmaceuticals by 7.7% in the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after buying an additional 115,000 shares during the period. Corient Private Wealth LP bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $1,313,000. Finally, Empowered Funds LLC raised its holdings in Arrowhead Pharmaceuticals by 661.6% during the 1st quarter. Empowered Funds LLC now owns 137,220 shares of the biotechnology company’s stock valued at $8,604,000 after buying an additional 119,202 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported interim Phase 1/2a results for ARO-MAPT, its investigational Alzheimer’s treatment. The drug reportedly crossed the blood-brain barrier and produced up to a 73% reduction in tau, a protein associated with Alzheimer’s disease. The results support the potential of Arrowhead’s TRiM platform for delivering RNA therapies into the central nervous system. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: UBS initiated coverage of ARWR with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reiterated Buy ratings with targets of $115 and $120, respectively. The targets reflect analysts’ confidence in Arrowhead’s pipeline and potential long-term upside. Arrowhead Pharmaceuticals Receives a New Rating from UBS
• Positive Sentiment: HC Wainwright projects Arrowhead could earn $9.61 per share in fiscal 2031, a sharp contrast with the expected loss of $3.62 per share for the current fiscal year. This highlights the firm’s view that commercialization of Arrowhead’s pipeline could significantly improve future profitability.
• Neutral Sentiment: The ARO-MAPT findings are interim, early-stage results and will require confirmation in larger, later-stage trials before they can support regulatory approval or commercial revenue.
• Negative Sentiment: After the initial data-driven surge, investors may be taking profits and reassessing valuation. Arrowhead remains unprofitable, recently missed quarterly EPS expectations, and faces substantial clinical, regulatory, and execution risks.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.